Yahoo
NasdaqGM - Delayed Quote USD

Omeros Corporation (OMER)

18.95 -0.16 (-0.84%)
At close: September 4 at 4:00:00 PM EDT
19.03 +0.08 (+0.42%)
After hours: September 4 at 7:30:03 PM EDT
Trade Omeros on Coinbase
Chart Range Bar
Loading chart for OMER

What's happening with OMER?

39m ago
Powered by Yahoo Scout

Omeros Corporation (OMER) has reported significant momentum with its newly launched drug, Yartemlia, showcasing impressive sales figures and transitioning to profitability. Analysts are optimistic about the company's future, despite recent regulatory challenges in Europe.

Powered by Yahoo Scout
  • Previous Close 19.11
  • Open 18.92
  • Bid 9.39 x 200
  • Ask 16.29 x 200
  • Day's Range 18.90 - 19.23
  • 52 Week Range 3.94 - 19.65
  • Volume 892,192
  • Avg. Volume 2,058,126
  • Market Cap (intraday) 1.372B
  • Beta (5Y Monthly) 2.60
  • PE Ratio (TTM) 11.48
  • EPS (TTM) 1.65
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 33.00

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

www.omeros.com

175

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

OMER
10.30%
S&P 500 (^GSPC)
12.75%

1-Year Return

OMER
353.35%
S&P 500 (^GSPC)
18.71%

3-Year Return

OMER
435.31%
S&P 500 (^GSPC)
70.93%

5-Year Return

OMER
20.32%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 28.53M
Earnings 13.23M
Profit Margin 46.38%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
0
20M
40M
60M
80M
0.0%
200.0%
400.0%

Analyst Insights

View More

Top Analyst

D. Boral Capital
64/100
Latest Rating
Buy

Analyst Price Targets

33.00
33.00 Average
18.95 Current
33.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/26/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 40 -> 33

Statistics

View More

Valuation Measures

Annual
As of 9/3/2026
  • Market Cap

    1.38B

  • Enterprise Value

    1.39B

  • Trailing P/E

    11.59

  • Forward P/E

    79.37

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    39.46

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    36.21

  • Enterprise Value/EBITDA

    148.81

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    324.88%

  • Return on Assets (ttm)

    -18.68%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    38.42M

  • Net Income Avi to Common (ttm)

    116.53M

  • Diluted EPS (ttm)

    1.65

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    131.95M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    183.31M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

18.95 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: